Undenatured Type II Collagen Enters a Blinded Trial for Knee Osteoarthritis Pain
A randomized, double-blind, three-arm trial is preparing to test whether undenatured type II collagen can ease pain in adults with knee osteoarthritis. The study will compare two collagen products, Nuvicol II and Nuvicol SII, against placebo in 120 participants, with treatment given once daily for 4 months.
The design is straightforward but clinically important. Knee osteoarthritis remains one of the most common causes of persistent pain and mobility loss in adults over 30, and patients often move through a narrow corridor of options: exercise, weight management, analgesics, injections, and, in advanced cases, surgery. A treatment that could reduce pain while limiting reliance on rescue medication would fill a meaningful gap, particularly for patients whose symptoms are chronic but not yet severe enough to justify invasive care.
Why This Trial Matters in Everyday Osteoarthritis Care
The study focuses on adults with persistent knee pain and functional osteoarthritis grades I to III by modified American College of Rheumatology criteria. Entry also requires a baseline visual analog scale pain score of at least 30 mm, which selects for patients with clinically relevant symptoms rather than mild, intermittent discomfort.
One sentence captures the practical challenge facing this population: many patients need symptom relief before structural disease becomes severe enough to drive more aggressive interventions.
The trial excludes participants using narcotic analgesics, steroidal anti-inflammatory drugs, immunosuppressants, glucosamine, chondroitin sulfate, collagen products, hyaluronic infiltrations, or other joint-health supplements. Those restrictions tighten the signal the investigators are trying to capture. If pain improves, the change is less likely to be confounded by overlapping nutraceuticals or stronger anti-inflammatory therapies. The protocol also excludes people with inflammatory rheumatologic disease, severe systemic illness, pregnancy, and body mass index above 32 kg/m2, narrowing the cohort to a more homogeneous osteoarthritis population.
Two Sources, One Mechanistic Question
The intervention itself is built around a biologic premise rather than a traditional analgesic mechanism. Nuvicol II contains undenatured type II collagen from chicken source, while Nuvicol SII contains undenatured type II collagen from salmon source. Each product is dosed at 40 mg orally once daily for 4 months.
In osteoarthritis, joint discomfort is not just a pain-processing problem. Cartilage breakdown, low-grade synovial inflammation, altered biomechanics, and muscle weakness all interact to worsen symptoms. A therapy built around undenatured collagen is being tested in that context because oral exposure may influence immune tolerance pathways and downstream inflammatory signaling, potentially affecting cartilage catabolism and symptom burden rather than simply masking pain perception. Whether that biological hypothesis translates into measurable improvement remains the central question of the study.
Placebo capsules containing maltodextrin and magnesium stearate provide the control arm, allowing the investigators to judge whether any symptom improvement exceeds expectation, background fluctuation, or regression to the mean.
Pain, Function, and Cartilage Biomarkers Will All Be Measured
The primary endpoint is change in joint pain intensity measured by a 10-cm visual analog scale from baseline to 16 weeks. That endpoint is clinically direct and easy to interpret at the bedside. When a patient with osteoarthritis says the knee hurts less, the first question is whether the pain reduction is real, reproducible, and enough to affect walking, climbing stairs, or sleeping.
Secondary outcomes add a broader view of disease impact. The Knee injury and Osteoarthritis Outcome Score, or KOOS, will track pain, symptoms, activities of daily living, sport and recreation function, and knee-related quality of life. The Western Ontario and McMaster Universities Osteoarthritis Index, or WOMAC, will measure pain, stiffness, and physical function. Together, those instruments move beyond a single number and ask whether treatment changes the way the knee actually behaves in daily life.
The protocol also records concomitant analgesic use. In osteoarthritis trials, rescue medication often tells a practical story that symptom scores alone can miss. A patient may report modest pain reduction yet still reach for the same number of tablets every day; another may reduce medication use even if scale-based improvement is more modest. Both patterns matter clinically.
Muscle Function and Biomarkers Could Separate Symptom Relief From Joint Biology
The trial reaches deeper than questionnaires. Isometric and isokinetic knee muscle function will be measured with a Biodex System 3 dynamometer at baseline, 8 weeks, and 16 weeks. That matters because quadriceps inhibition and deconditioning often amplify knee osteoarthritis disability. If a treatment reduces pain enough to permit stronger contraction or better performance on dynamometry, the functional benefit may extend beyond subjective relief.
Cartilage oligomeric matrix protein, or COMP, and urinary C-terminal telopeptide of type II collagen, or CTX-II, will be tracked as biomarkers of cartilage degradation and treatment response. These measures are not perfect surrogates, and they do not replace patient-centered outcomes. Still, they offer a window into whether the intervention influences cartilage turnover, which is one of the more biologically relevant questions in osteoarthritis research.
Safety monitoring includes renal and hepatic blood parameters, blood hematology, and adverse events throughout the 16-week study period. That is an essential feature even for products marketed as dietary supplements. In musculoskeletal care, the assumption that a supplement is automatically benign has too often outpaced the evidence.
A Carefully Chosen Cohort May Clarify Signal, but It Will Also Narrow Generalizability
The study plans to enroll adults aged 31 years and older, across sexes, at a single site in Murcia, Spain. Its double-blind structure and triple masking of participants, investigators, and outcome assessors strengthen internal validity. The 4-month duration is long enough to detect sustained symptom movement, yet short enough to keep the focus on early efficacy and tolerability rather than late structural change.
A single-center design can be efficient, but it also places limits on how broadly the findings can be applied. Patients with higher body mass index, inflammatory musculoskeletal disease, or concurrent supplement use are excluded, so the eventual results will speak most directly to a selected osteoarthritis population rather than the full spectrum seen in routine practice.
The sample size is estimated at 120, which should provide an initial readout on pain, function, and tolerability, but not definitive answers about long-term structural disease modification. If either collagen formulation improves pain and reduces analgesic use without safety concerns, the next question will be whether that effect is consistent enough to justify larger multicenter testing. If the two products diverge, formulation and source may prove clinically relevant, especially if one source yields better symptom control or biomarker shifts than the other.
For now, the trial is set up to answer a practical question that matters at the bedside: can a daily capsule of undenatured type II collagen do more than placebo for persistent knee osteoarthritis pain, and can it do so without adding safety problems during 16 weeks of treatment?